Reviva Pharmaceuticals (NASDAQ:RVPH) Now Covered by Analysts at Roth Mkm

Roth Mkm assumed coverage on shares of Reviva Pharmaceuticals (NASDAQ:RVPH) in a report released on Friday,Benzinga reports. The firm issued a buy rating and a $7.00 price objective on the stock.

Separately, EF Hutton Acquisition Co. I raised shares of Reviva Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 23rd. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Reviva Pharmaceuticals has an average rating of “Buy” and an average target price of $11.25.

Reviva Pharmaceuticals Trading Up 0.5 %

Shares of RVPH stock opened at $1.88 on Friday. The firm has a market capitalization of $62.87 million, a price-to-earnings ratio of -1.69 and a beta of -0.12. The business’s 50-day moving average price is $1.56 and its 200-day moving average price is $1.29. Reviva Pharmaceuticals has a 12 month low of $0.60 and a 12 month high of $4.83.

Hedge Funds Weigh In On Reviva Pharmaceuticals

An institutional investor recently raised its position in Reviva Pharmaceuticals stock. Geode Capital Management LLC raised its position in shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 17.9% in the third quarter, according to its most recent filing with the SEC. The firm owned 278,496 shares of the company’s stock after purchasing an additional 42,376 shares during the quarter. Geode Capital Management LLC owned approximately 0.83% of Reviva Pharmaceuticals worth $401,000 at the end of the most recent quarter. 63.18% of the stock is currently owned by hedge funds and other institutional investors.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.